Incorporating patient preferences into drug development and regulatory decision making: Results from a quantitative pilot study with cancer patients, carers, and regulators

Postmus, D., Mavris, M., Hillege, H. L., Salmonson, T., Ryll, B., Plate, A., Moulon, I., Eichler, H-G., Bere, N. & Pignatti, F., May-2016, In : Clinical Pharmacology & Therapeutics. 99, 5, p. 548-554 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard


  • Incorporating patient preferences into drug development and regulatory decision making

    Final publisher's version, 319 KB, PDF document

    Request copy


Currently, patient preference studies are not required to be included in marketing authorization applications to regulatory authorities, and the role and methodology for such studies have not been agreed upon. The European Medicines Agency (EMA) conducted a pilot study to gain experience on how the collection of individual preferences can inform the regulatory review. Using a short online questionnaire, ordinal statements regarding the desirability of different outcomes in the treatment of advanced cancer were elicited from 139 participants (98 regulators, 29 patient or carers, and 12 healthcare professionals). This was followed by face-to-face meetings to gather feedback and validate the individual responses. In this article we summarize the EMA pilot study and discuss the role of patient preference studies within the regulatory review. Based on the results, we conclude that our preference elicitation instrument was easy to implement and sufficiently precise to learn about the distribution of the participants' individual preferences.

Original languageEnglish
Pages (from-to)548-554
Number of pages7
JournalClinical Pharmacology & Therapeutics
Issue number5
Early online date17-Feb-2015
Publication statusPublished - May-2016

ID: 31135755